PIK3CA and KRAS mutations predict for response to everolimus therapy: Now that's RAD001

Journal of Clinical Investigation

Volumn 120, Issue 8, 2010, Pages 2655-2658

  Mohseni, Morassa ^a   Park, Ben Ho ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PROTEIN KINASE B; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; DNA DAMAGE; DRUG RESPONSE; GENE; HUMAN; NOTE; ONCOGENE K RAS; PIK 3CA GENE; PREDICTION; PRIORITY JOURNAL; PROTO ONCOGENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 77955290481     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI44026     Document Type: Note

References (13)

1. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med. 2002;8(4 Suppl):S14-S18.
2. Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
3. Paez JG, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500.
4. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101(19):1308-1324.
5. Di Nicolantonio F, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010;120(8):2858-2866.
6. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627-644.
7. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 124(3):471-484.
8. Wood LD, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318(5853):1108-1113.
9. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006;94(4):455-459.
10. Houghton PJ. Everolimus. Clin Cancer Res. 2010; 16(5):1368-1372.
11. Di Nicolantonio F, et al. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A. 2008;105(52):20864-20869.
12. Gustin JP, et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A. 2009;106(8):2835-2840.
13. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science. 1993; 260(5104):85-88.